Gossamer Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Gossamer Bio announced a workforce reduction and missed the primary endpoint in its Phase 3 PROSERA trial for seralutinib, leading to strategic re-evaluation and a need for additional capital.
NASDAQ
10-K: Gossamer Bio Reports 2024 Results, Highlights Seralutinib Development and Chiesi Collaboration
Gossamer Bio's 2024 10-K filing details the company's focus on seralutinib for pulmonary hypertension, its collaboration with Chiesi, and ongoing clinical trials.
NASDAQ
Gossamer Bio's 2023 10-K filing highlights the company's focus on developing seralutinib for pulmonary hypertension, including ongoing Phase 3 trials and future plans for PH-ILD.